* Somalogic Inc SLGC.OQ SLGC.O is expected to show a
rise in
quarterly revenue when it reports results on August 14.
* The Boulder Colorado-based company is expected to report
a
40.2% increase in revenue to $19.825 million from $14.14 million
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Somalogic Inc is
for a
loss of 16 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Somalogic
Inc is
$6, above its last closing price of $2.07.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.22 -0.22 -0.18 Beat 16.9
Dec. 31 2023 -0.21 -0.26 Missed -23.8
Sep. 30 2022 -0.20 -0.20 -0.18 Beat 8.5
Jun. 30 2022 -0.20 -0.18 -0.13 Beat 26.4
Mar. -0.16 -0.16 -0.02 Beat 87.3
31 2022
Dec. 31 2021 -0.11 -0.13 -0.13 Met -2
This summary was machine generated August 12 at 02:06 GMT. All
figures in US dollars unless otherwise stated